What is the price target for DRMA stock?
7 analysts have analysed DRMA and the average price target is 4.08 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 1.36.
DERMATA THERAPEUTICS INC (DRMA) Forecast, Price Target & Analyst Ratings
NASDAQ:DRMA • US2498455045
Current stock price
1.36 USD
+0.02 (+1.49%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DERMATA THERAPEUTICS INC (DRMA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.54
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
+ 200.00%
From current price of $1.36 to mean target of $4.08, Based on 7 analyst forecasts
Low
$4.04
Median
$4.08
High
$4.20
Price Target Revisions
1 Month
-60.00%
3 Months
-60.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for DRMA. The average price target is 4.08 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 1.36.
The average price target has been revised downward by 60% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
DRMA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DRMA.
In the previous month the buy percentage consensus was at a similar level.
DRMA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-21 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-21 | Maxim Group | Maintains | Buy -> Buy |
| 2024-08-21 | Maxim Group | Maintains | Buy -> Buy |
| 2023-03-23 | Maxim Group | Maintains | Buy |
| 2021-09-21 | Brookline Capital | Initiate | Buy |
| 2021-09-14 | Maxim Group | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.54
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 87.99%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
26.39%
EPS (3 Months)
26.39%
Next Earnings Summary
DRMA is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.54 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2027
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 650.00% | ||||||||
| EBITDA YoY % growth | -4.469M | -3.173M 29.01% | -7.857M -147.65% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.471M | -3.173M 29.03% | -7.857M -147.63% | -9.675M -23.13% | -8.042M 16.88% | -12.513M -55.60% | -7.774M 37.88% | N/A -26.83% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2,208.00 67.61% | -547.50 75.20% | -153.30 72.00% | -9.33 93.91% | N/A 75.95% | N/A 32.27% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 87.99% | -0.58 64.98% | -0.62 62.29% | -0.51 66.45% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.212M 5.45% | -2.402M -35.51% | -2.592M -47.20% | -2.679M -40.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
DERMATA THERAPEUTICS INC / DRMA Forecast FAQ
Can you provide the upcoming earnings date for DERMATA THERAPEUTICS INC?
DERMATA THERAPEUTICS INC (DRMA) will report earnings on 2026-05-12.
What are the consensus estimates for DRMA stock next earnings?
The consensus EPS estimate for the next earnings of DERMATA THERAPEUTICS INC (DRMA) is -0.54 USD and the consensus revenue estimate is 0 USD.
What is the number of analysts for DRMA stock?
The number of analysts covering DERMATA THERAPEUTICS INC (DRMA) is 7.